The Short-Term Efficacy of a Monoclonal Antibody Fragment (brolucizumab) for Treating Neovascular Age-Related Macular Degeneration. Ukr. j. ophthalmol. 2024, No. 3, 28-32. https://doi.org/10.31288/oftalmolzh202432832.